Customize SCRL19 Antibody

Description

Overview of CA19-9 (SLea) Antibody (Clone 121SLE)

Target: Sialyl Lewis a (SLea) antigen, a tumor-associated carbohydrate antigen expressed in adenocarcinomas (e.g., pancreatic, colorectal) .
Isotype: IgMκ
Host Species: Mouse
Applications:

ELISA (sensitivity: 0.001–100 µg/mL)
Flow cytometry (0.5–1.0 µg/million cells)
Immunohistochemistry (1–2 µg/mL)

Key Findings

Diagnostic Utility:
- Validated for detecting CA19-9 in serum samples of pancreatic cancer patients via ELISA, with a linear detection range of 0–100 µg/mL .
- Demonstrated specificity for SLea glycolipids in IHC, showing minimal cross-reactivity with unrelated mucins .
Functional Studies:
- In flow cytometry, it binds cell-surface CA19-9 on human cancer cell lines (e.g., SW1990, AsPC-1) with an optimal dose of 1.0 µg/million cells .
- Unlike IgG antibodies, IgM-based clones like 121SLE exhibit higher avidity due to pentameric structure, enhancing pathogen neutralization in early immune responses .
Comparative Performance:

Parameter Anti-CA19-9 (121SLE) Typical Monoclonal IgG
Half-Life ~5 days (IgM) 21–28 days (IgG)
Complement Activation Strong (via C1q) Moderate
Tissue Penetration Limited (large size) High

Parameter	Anti-CA19-9 (121SLE)	Typical Monoclonal IgG
Half-Life	~5 days (IgM)	21–28 days (IgG)
Complement Activation	Strong (via C1q)	Moderate
Tissue Penetration	Limited (large size)	High

Challenges in Antibody Validation

Specificity Issues:
Over 50% of commercial antibodies fail in ≥1 application due to non-specific binding . Clone 121SLE was confirmed via immunodiffusion and Workshop TD6 assays, reducing off-target risks .
Manufacturing Variability:
Batch consistency is critical; clone 121SLE is affinity-purified from Sp2/0 hybridoma cultures to ensure reproducibility .

Future Directions

Engineering Efforts:
- Chimerization to IgG isotypes to extend half-life .
- Conjugation with biotin/fluorophores for multiplex assays (e.g., sandwich ELISA with IgG partners) .
Broad-Spectrum Potential:
Lessons from broadly neutralizing antibodies like SC27 (targeting SARS-CoV-2) suggest targeting conserved epitopes could improve CA19-9 antibody efficacy against heterogeneous tumors .

Product Specs

Buffer

Preservative: 0.03% ProClin 300; Constituents: 50% Glycerol, 0.01M Phosphate Buffered Saline (PBS), pH 7.4

Form

Liquid

Lead Time

14-16 week lead time (made-to-order)

Synonyms

SCRL19 antibody; At3g27503 antibody; MMJ24 antibody; Defensin-like protein 241 antibody; S locus cysteine-rich-like protein 19 antibody; Protein SCRL19 antibody; SCR-like protein 19 antibody

Target Names

SCRL19

Uniprot No.

P82638

Target Background

Database Links

KEGG: ath:AT3G27503

STRING: 3702.AT3G27503.1

UniGene: At.63251

Protein Families

DEFL family

Subcellular Location

Secreted.

Q&A

FAQs for Researchers on SC27 Antibody (Potential Typo: SCRL19)
Note: Based on search results, "SC27" is the antibody referenced in peer-reviewed studies. "SCRL19" is not mentioned in available literature, so this FAQ assumes a typographical error.

Advanced Research Questions

What experimental models validate SC27’s efficacy in vivo?
- Mouse Models: SC27 reduced viral load by 4 logs in BALB/c mice challenged with Beta and Delta variants .
- Nonhuman Primates: Pending (next-step trials required for IND approval) .
  Methodological Gap: Current models lack humanized ACE2 receptors, potentially underestimating tissue-specific immunity .

How do public antibody responses influence SC27’s utility in vaccine design?
SC27 belongs to the "class 1/4" antibody family, characterized by:
- IGHV/IGKV Pairing: Recurrent IGHV3-53/IGKV1-9 usage in convalescent donors .
- CDR H3 Motifs: 14-amino-acid loops with conserved glycine-serine hinges .
  Methodological Insight: Use single-cell BCR sequencing to identify clonal lineages in vaccinated cohorts, then correlate with neutralization titers .

What contradictions exist in SC27’s reported neutralization breadth?
- Data Conflict: While SC27 neutralizes 12 coronaviruses in vitro , its efficacy against feline coronaviruses (e.g., FIPV) remains untested, raising questions about true pan-coronavirus potential.
- Resolution Strategy: Expand testing to underrepresented Coronaviridae subgenera using pseudotyped virus libraries .

How can SC27 inform assay development for humoral immunity studies?
Key parameters for quantitative serology:

Assay Component	SC27-Based Optimization
Antigen Design	Trimeric spike with stabilized S2 cryptic site
Cut-off Threshold	>1.5 OD₄₅₀nm (99% specificity)
Cross-Reactivity Control	Pre-adsorption with seasonal CoV antigens

Source: Multiplexed serological platforms .

Data Contradiction Analysis

Conflict: SC27’s reliance on conserved epitopes vs. observed variability in antibody durability .
Hypothesis: Epitope conservation may not guarantee long-term efficacy if antibody half-life is compromised by glycosylation shifts.
Resolution: Perform longitudinal epitope mapping using hydrogen-deuterium exchange mass spectrometry (HDX-MS) over 12 months post-infection .

Quick Inquiry

Personal Email Detected

Please use an institutional or corporate email address for inquiries. Personal email accounts ( such as Gmail, Yahoo, and Outlook) are not accepted. *

Name*

Email*

Phone

Country

Source

Quantity&Size*

Product Name

Message

SCRL19 Antibody